Skip to content

Halozyme Therapeutics HALO Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization

Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization at other companies

JPMorgan Chase logo
JPMorgan ChaseJPM
$36.77B+12.1%
U.S. Bancorp logo
U.S. BancorpUSB
$8.47B+3.9%
Deere & Company logo
Deere & CompanyDE
$8.04B+6.4%
U.S. Bancorp logo
U.S. BancorpUSB
$4.7B+2.5%
Chevron logo
ChevronCVX
$129.2B+62.3%
Deere & Company logo
Deere & CompanyDE
$4.2B+1.6%

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's property, plant, and equipment and operating lease right-of-use asset, after accumulated depreciation and amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's property, plant, and equipment and operating lease right-of-use asset, after accumulated depreciation and amortization?
Halozyme Therapeutics (HALO) reported property, plant, and equipment and operating lease right-of-use asset, after accumulated depreciation and amortization of $82.23M in Q1 2026.
How has Halozyme Therapeutics's property, plant, and equipment and operating lease right-of-use asset, after accumulated depreciation and amortization changed year-over-year?
Halozyme Therapeutics's property, plant, and equipment and operating lease right-of-use asset, after accumulated depreciation and amortization increased by 12.9% year-over-year, from $72.82M to $82.23M.
What is the long-term trend for Halozyme Therapeutics's property, plant, and equipment and operating lease right-of-use asset, after accumulated depreciation and amortization?
Over 5 years (2020 to 2025), Halozyme Therapeutics's property, plant, and equipment and operating lease right-of-use asset, after accumulated depreciation and amortization has grown at a 50.6% compound annual growth rate (CAGR), from $10.59M to $82.14M.
What does property, plant, and equipment and operating lease right-of-use asset, after accumulated depreciation and amortization mean?
This represents the net book value of long-term tangible assets and right-of-use assets from operating leases, after accounting for depreciation and amortization. It reflects the company's investment in physical infrastructure and leased facilities required for long-term operations. This metric is a key indicator of capital intensity and the scale of the company's physical footprint.